June 25, 2024
Polycystic Ovary Syndrome (PCOS) Treatment Market

Market Is Estimated To Witness High Growth Owing To prevalence and diagnosis rates

The Polycystic Ovary Syndrome (PCOS) Treatment Market is estimated to be valued at US$ 1,086.6 million in 2023 and is expected to exhibit a CAGR of 4.86% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Polycystic ovary syndrome (PCOS) is a hormonal disorder common among women of reproductive age. PCOS is characterized by enlarged ovaries with small cysts on the outer edges. It causes irregular or extended menstrual cycles and excess androgen (male hormone) levels. Treatments aim to regulate menstrual cycles and reduce androgen levels. Medications used include oral contraceptives, metformin, anti-androgens such as spironolactone, and other fertility drugs.

Market Dynamics:

The PCOS treatment market is driven by rising prevalence and growing awareness about the condition. According to the Office on Women’s Health, PCOS affects around 1 in 10 women in the U.S. The condition often goes undiagnosed as many women dismiss irregular periods or excess hair growth as normal. Advancements in diagnostic techniques and higher screening are leading to increased diagnosis rates. Oral contraceptives remain the first line of treatment due to their effectiveness in regulating periods and reducing acne and excess hair growth symptoms. Metformin is commonly prescribed to address insulin resistance and weight management in women with PCOS.

SWOT Analysis

Strength: PCOS treatment market has robust R&D pipeline with over 50 drugs in development or launched. The wide range of oral contraceptive and hormonal therapies provide effective treatment options. Developing generics are more affordable treatment alternatives.

Weakness: Lack of standardized diagnostic criteria leads to under-diagnosis of PCOS. Long-term effects of PCOS medications remain unclear. Compliance to lifestyle changes is challenging.

Opportunity: Growth in awareness campaigns help identify overlooked PCOS cases. Rise in obese population increases predisposition to PCOS. Novel drug delivery methods can improve therapy effectiveness and compliance.

Threats: Safety concerns over long-term usage of hormonal drugs hamper product adoption. Patent expiries of blockbuster drugs increase generic competition. Stringent regulations delay product approvals.

Key Takeaways

The Global PCOS Treatment Market Growth  is expected to witness high growth, exhibiting CAGR of 4.86% over the forecast period, due to increasing awareness raising activities by various healthcare organizations.

Regional analysis: North America dominates the PCOS treatment market currently due to high healthcare spending and early access to innovative therapies. However, Asia Pacific is expected to grow at the fastest pace during the forecast period due to rising obesity prevalence, growing medical tourism, and increasing government initiatives to spread awareness regarding PCOS.

Key players: Key players operating in the PCOS treatment market are Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddy’s Laboratories, Cadila Pharmaceuticals, Novartis International AG, Concordia Pharmaceuticals Inc., Covis Pharmaceuticals, Inc., Cardinal Health, Aphena Pharma Solutions Tennessee, Inc., Mylan N.V., Evotec SE, McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin Pharmaceutical and Sun Pharmaceutical Industries Ltd., Bayer AG.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it